PDL1 Testing for Lung Cancer [A Test in Focus]
Immunotherapies have recently emerged as a therapeutic option for patients with non-small-cell lung carcinoma (NSCLC). Therapies have been approved for both first and second-line treatments of NSCLC tumors with specific patterns of PD-L1 expression. Mayo Clinic Laboratories offers three PD-L1 clones for assessing patient response to specific therapies.
Anja Roden, M.D., gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.
- Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual (Mayo ID: 22C3)
- Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual (Mayo ID: SP263)
- Programmed Death-Ligand 1 (PD-L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual (Mayo ID: SP142)
- Identification of neoplasms expressing programmed cell death 1-ligand 1.
Specimen Type: Tissue
Supplies: Pathology Packaging Kit (T554)
Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue
Additional Information: One slide will be stained with hematoxylin and eosin and returned.